Patient expectations from lens surgery are changing, with an increasing desire to be spectacle free as they continue to lead highly active and social lifestyles until much later in life.
Whether your patients are having cataract surgery or visiting you for refractive enhancement, our complete family of trifocal IOLs are clinically proven to provide them with the best visual outcomes.
Our family of trifocal IOLs use Rayner’s patented diffractive profile that was designed in partnership with a leading European technology institute. This new design of diffractive technology is the most advanced optic in our history and possibly the most advanced in the industry. The diffractive surface is a construct of two profiles to form our patented design:
Graphical representations only of diffractive surface pattern.
FEATURES
• 16 diffractive rings/steps
• 4.5 mm diffractive zone
• >4.5 mm monofocal, distance
PATIENT BENEFITS
• Reduces visual disturbances
• Developed to be less dependent on pupil size or lighting conditions
• Improves distance vision in mesopic condition
• 89% of light is transmitted to the retina with a pupil of 3.0 mm
• Half the light is allocated for distance
• Remaining light is divided between near and intermediate vision
Our trifocal optic improves intermediate visual acuity, enabling patients to feel more comfortable transitioning from near to distance activities
technologyComparable outcomes
In a retrospective study of RayOne Trifocal and Sulcoflex Trifocal in 40 eyes, the defocus curve shows comparable visual acuity results and reports similar outcomes.1
In a prospective study of 60 eyes, a statistically significant difference favouring the RayOne Trifocal versus the FineVision POD F was achieved in an objective evaluation of photic phenomenon.2
In a prospective comparative study of 48 eyes, the RayOne Trifocal group is associated with better scores for glare, symptoms and near and distance VA against the PanOptix Trifocal group.1
In a prospective study of 16 eyes implanted with RayOne Trifocal, 100% of patients achieved spectacle independence and agreed they would have the operation again at 1 month follow up.3
